Abstract: This disclosure relates to curable silicone rubber compositions suitable for use in the manufacture of cured-in-place gaskets (CIPGs), silicone elastomers resulting from the cure of such compositions and methods for making CIPGs from such compositions. The inclusion of a compound having at least two trialkoxysilyl groups, at least two dialkoxyalkylsilyl groups or a mixture of two or more trialkoxysilyl groups, and dialkoxyalkylsilyl groups per molecule selected from: (i) (R10)z (R11)3-z Si—(W)—Si (R11)3-z (R10)z; or (ii) 1,3,5-tris[3-((R10)z(R11)3-z Si)-D]-1,3,5-triazine-2,4,6(1H,3H,5H)-trione where each R11 is independently an alkoxy group having 1 to 6 carbons; each R10 is independently R11 or an alkyl group having 1 to 6 carbons, z is 0 or 1; W is a linear or branched alkylene having 1 to 12 carbons; and D is an alkylene group having from 1 to 6 carbons; provides CIPGs which show both a good adhesion to aluminium and a good compression set.

Abstract: An embodiment generates an initial set of training data from monitoring data. The initial set of training data is generated by combining outputs from a plurality of pretrained classifiers. The embodiment trains a new classification model using the initial set of training data to identify anomalies in monitoring data. The embodiment performs a multiple-level clustering of the data samples resulting in a plurality of clusters of sub-clusters of data samples, and generates a review list of data samples by selecting a representative data sample from each of the clusters. The embodiment receives an updated data sample from the expert review that includes a revised target classification for at least one of the data samples of the expert review list. The embodiment then trains another replacement classification model using a revised set of training data that includes the updated data sample and associated revised target classification.

Abstract: The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a.

Abstract: The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a.